Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check5 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; 'Back to Top' link removed.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated to include information on Lung cancer under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.SummaryDifference0.4%
- Check19 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as a list of publications related to a clinical study. Notably, the MedlinePlus related topics have been expanded to include drug safety and counterfeit drugs.SummaryDifference21%
- Check26 days agoChange DetectedThe webpage has been updated with new dates for future events, specifically adding estimated last update dates in August 2025, while removing outdated dates from January 2022.SummaryDifference1.0%
- Check33 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.